163 related articles for article (PubMed ID: 9668196)
1. Thrombin inhibitor design.
Sanderson PE; Naylor-Olsen AM
Curr Med Chem; 1998 Aug; 5(4):289-304. PubMed ID: 9668196
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
[TBL] [Abstract][Full Text] [Related]
3. Modulating platelet function with selective thrombin inhibitors.
Verstraete M
Haemostasis; 1996 Oct; 26 Suppl 4():70-7. PubMed ID: 8979113
[TBL] [Abstract][Full Text] [Related]
4. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
Cella G; Girolami A; Sasahara AA
Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
[No Abstract] [Full Text] [Related]
5. Design and synthesis of thrombin inhibitors: analogues of MD-805 with reduced stereogenicity and improved potency.
Brundish D; Bull A; Donovan V; Fullerton JD; Garman SM; Hayler JF; Janus D; Kane PD; McDonnell M; Smith GP; Wakeford R; Walker CV; Howarth G; Hoyle W; Allen MC; Ambler J; Butler K; Talbot MD
J Med Chem; 1999 Nov; 42(22):4584-603. PubMed ID: 10579821
[TBL] [Abstract][Full Text] [Related]
6. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors.
Rupin A; Mennecier P; de Nanteuil G; Laubie M; Verbeuren TJ
Thromb Res; 1995 May; 78(3):217-25. PubMed ID: 7631302
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
Reers M; Koschinsky R; Dickneite G; Hoffmann D; Czech J; Stüber W
J Enzyme Inhib; 1995; 9(1):61-72. PubMed ID: 8568567
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.
Tapparelli C; Metternich R; Ehrhardt C; Zurini M; Claeson G; Scully MF; Stone SR
J Biol Chem; 1993 Mar; 268(7):4734-41. PubMed ID: 8444849
[TBL] [Abstract][Full Text] [Related]
9. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.
Brandstetter H; Turk D; Hoeffken HW; Grosse D; Stürzebecher J; Martin PD; Edwards BF; Bode W
J Mol Biol; 1992 Aug; 226(4):1085-99. PubMed ID: 1518046
[TBL] [Abstract][Full Text] [Related]
10. Thrombin active site inhibitors.
Das J; Kimball SD
Bioorg Med Chem; 1995 Aug; 3(8):999-1007. PubMed ID: 7582987
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
Nilsson T; Sjöling-Ericksson A; Deinum J
J Enzyme Inhib; 1998 Feb; 13(1):11-29. PubMed ID: 9879511
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors.
Rewinkel JB; Lucas H; Smit MJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA
Bioorg Med Chem Lett; 1999 Oct; 9(19):2837-42. PubMed ID: 10522702
[TBL] [Abstract][Full Text] [Related]
14. A family of arginal thrombin inhibitors related to efegatran.
Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV
Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715
[TBL] [Abstract][Full Text] [Related]
15. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
16. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
17. Synthetic selective inhibitors of thrombin.
Okamoto S; Hijikata-Okunomiya A
Methods Enzymol; 1993; 222():328-40. PubMed ID: 8412802
[No Abstract] [Full Text] [Related]
18. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Callas DD; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.
Girnys EA; Sobczyk-Kojiro K; Mosberg HI
Chem Biol Drug Des; 2010 Jan; 75(1):35-9. PubMed ID: 19954432
[TBL] [Abstract][Full Text] [Related]
20. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
